Microsporidiosis secondary prevention: Difference between revisions
No edit summary |
Ahmed Younes (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Microsporidiosis}} | {{Microsporidiosis}} | ||
{{CMG}};{{AE}}{{AY}} | |||
==Overview== | |||
{{ | ==== | ||
==References== | |||
{{Reflist|2}} | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
Revision as of 13:10, 28 June 2017
|
Microsporidiosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Microsporidiosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Microsporidiosis secondary prevention |
|
Risk calculators and risk factors for Microsporidiosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Ahmed Younes M.B.B.CH [2]
Overview
==
References
Secondary Prevention
Prevention of Recurrence
Treatment for ocular microsporidiosis should be continued indefinitely because recurrence or relapse might follow treatment discontinuation (BIII). Whether treatment can be safely discontinued after immune restoration with ART is unknown, although it is reasonable, on the basis of the experience with discontinuation of secondary prophylaxis (chronic maintenance therapy) for other opportunistic infections during advanced HIV-1 disease, to discontinue chronic maintenance therapy if patients remain asymptomatic with regard to signs and symptoms of microsporidiosis and have a sustained (e.g. >6 months) increase in their CD4+ T lymphocyte counts to levels >200 cells/µL after ART (CIII).